Pregabalin Mylan

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
13-01-2023

Ingredient activ:

pregabalin

Disponibil de la:

Mylan Pharmaceuticals Limited

Codul ATC:

N03AX16

INN (nume internaţional):

pregabalin

Grupul Terapeutică:

Antiepileptics,

Zonă Terapeutică:

Anxiety Disorders; Epilepsy

Indicații terapeutice:

Neuropathic painPregabalin Mylan is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Mylan is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Mylan is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Rezumat produs:

Revision: 16

Statutul autorizaţiei:

Authorised

Data de autorizare:

2015-06-24

Prospect

                                B. PACKAGE LEAFLET
PACKAGE LEAFLET: INFORMATION FOR THE USER
PREGABALIN MYLAN 25 MG HARD CAPSULES
PREGABALIN MYLAN 50 MG HARD CAPSULES
PREGABALIN MYLAN 75 MG HARD CAPSULES
PREGABALIN MYLAN 100 MG HARD CAPSULES
PREGABALIN MYLAN 150 MG HARD CAPSULES
PREGABALIN MYLAN 200 MG HARD CAPSULES
PREGABALIN MYLAN 225 MG HARD CAPSULES
PREGABALIN MYLAN 300 MG HARD CAPSULES
pregabalin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pregabalin Mylan is and what it is used for
2.
What you need to know before you take Pregabalin Mylan
3.
How to take Pregabalin Mylan
4.
Possible side effects
5.
How to store Pregabalin Mylan
6.
Contents of the pack and other information
1.
WHAT PREGABALIN MYLAN IS AND WHAT IT IS USED FOR
Pregabalin Mylan contains the active substance pregabalin which
belongs to a group of medicines
used to treat epilepsy, neuropathic pain and Generalised Anxiety
Disorder (GAD) in adults.
PERIPHERAL AND CENTRAL NEUROPATHIC PAIN:
Pregabalin Mylan is used to treat long lasting pain caused
by damage to the nerves. A variety of diseases can cause peripheral
neuropathic pain, such as diabetes
or shingles. Pain sensations may be described as hot, burning,
throbbing, shooting, stabbing, sharp,
cramping, aching, tingling, numbness, pins and needles. Peripheral and
central neuropathic pain may
also be associated with mood changes, sleep disturbance, fatigue
(tiredness), and can have an impact
on physical and social functioning and overall quality of life.
EPILEPSY:
Pregabalin Mylan is used to treat a certain
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Pregabalin Mylan 25 mg hard capsules
Pregabalin Mylan 50 mg hard capsules
Pregabalin Mylan 75 mg hard capsules
Pregabalin Mylan 100 mg hard capsules
Pregabalin Mylan 150 mg hard capsules
Pregabalin Mylan 200 mg hard capsules
Pregabalin Mylan 225 mg hard capsules
Pregabalin Mylan 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pregabalin Mylan 25 mg hard capsules
Each hard capsule contains 25 mg of pregabalin.
Pregabalin Mylan 50 mg hard capsules
Each hard capsule contains 50 mg of pregabalin.
Pregabalin Mylan 75 mg hard capsules
Each hard capsule contains 75 mg of pregabalin.
Pregabalin Mylan 100 mg hard capsules
Each hard capsule contains 100 mg of pregabalin.
Pregabalin Mylan 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
Pregabalin Mylan 200 mg hard capsules
Each hard capsule contains 200 mg of pregabalin.
Pregabalin Mylan 225 mg hard capsules
Each hard capsule contains 225 mg of pregabalin.
Pregabalin Mylan 300 mg hard capsules
Each hard capsule contains 300 mg of pregabalin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Pregabalin Mylan 25 mg hard capsules
No. 4, light peach opaque cap and white opaque body, hard-shell
gelatin capsule filled with white to
off-white powder. The capsule is axially printed with MYLAN over PB25
in black ink on cap and
body.
Pregabalin Mylan 50 mg hard capsules
No. 3, dark peach opaque cap and white opaque body, hard-shell gelatin
capsule filled with white to
off-white powder. The capsule is axially printed with MYLAN over PB50
in black ink on cap and
body.
Pregabalin Mylan 75 mg hard capsules
No. 4, light peach opaque cap and light peach opaque body, hard-shell
gelatin capsule filled with
white to off-white powder. The capsule is axially printed with MYLAN
over PB75 in black ink on
cap and body.
Pregabalin Mylan 100 mg hard capsules
No. 3, dark peach opaque cap and dark peach opaque body, hard-shell
gelatin capsule filled wi
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 13-01-2023
Raport public de evaluare Raport public de evaluare bulgară 19-07-2017
Prospect Prospect spaniolă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 13-01-2023
Raport public de evaluare Raport public de evaluare spaniolă 19-07-2017
Prospect Prospect cehă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 13-01-2023
Raport public de evaluare Raport public de evaluare cehă 19-07-2017
Prospect Prospect daneză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 13-01-2023
Raport public de evaluare Raport public de evaluare daneză 19-07-2017
Prospect Prospect germană 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului germană 13-01-2023
Raport public de evaluare Raport public de evaluare germană 19-07-2017
Prospect Prospect estoniană 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 13-01-2023
Raport public de evaluare Raport public de evaluare estoniană 19-07-2017
Prospect Prospect greacă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 13-01-2023
Raport public de evaluare Raport public de evaluare greacă 19-07-2017
Prospect Prospect franceză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 13-01-2023
Raport public de evaluare Raport public de evaluare franceză 19-07-2017
Prospect Prospect italiană 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 13-01-2023
Raport public de evaluare Raport public de evaluare italiană 19-07-2017
Prospect Prospect letonă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 13-01-2023
Raport public de evaluare Raport public de evaluare letonă 19-07-2017
Prospect Prospect lituaniană 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 13-01-2023
Raport public de evaluare Raport public de evaluare lituaniană 19-07-2017
Prospect Prospect maghiară 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 13-01-2023
Raport public de evaluare Raport public de evaluare maghiară 19-07-2017
Prospect Prospect malteză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 13-01-2023
Raport public de evaluare Raport public de evaluare malteză 19-07-2017
Prospect Prospect olandeză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 13-01-2023
Raport public de evaluare Raport public de evaluare olandeză 19-07-2017
Prospect Prospect poloneză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 13-01-2023
Raport public de evaluare Raport public de evaluare poloneză 19-07-2017
Prospect Prospect portugheză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 13-01-2023
Raport public de evaluare Raport public de evaluare portugheză 19-07-2017
Prospect Prospect română 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului română 13-01-2023
Raport public de evaluare Raport public de evaluare română 19-07-2017
Prospect Prospect slovacă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 13-01-2023
Raport public de evaluare Raport public de evaluare slovacă 19-07-2017
Prospect Prospect slovenă 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 13-01-2023
Raport public de evaluare Raport public de evaluare slovenă 19-07-2017
Prospect Prospect finlandeză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 13-01-2023
Raport public de evaluare Raport public de evaluare finlandeză 19-07-2017
Prospect Prospect suedeză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 13-01-2023
Raport public de evaluare Raport public de evaluare suedeză 19-07-2017
Prospect Prospect norvegiană 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 13-01-2023
Prospect Prospect islandeză 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 13-01-2023
Prospect Prospect croată 13-01-2023
Caracteristicilor produsului Caracteristicilor produsului croată 13-01-2023
Raport public de evaluare Raport public de evaluare croată 19-07-2017

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor